ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. Seattle Genetics ™ proprietary technology employs synthetic, highly potent drugs attached to antibodies through stable linker systems. The linkers are designed to release the drug payload only under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.

Seattle Genetics is developing brentuximab vedotin in collaboration with Millennium: The Takeda Oncology Company, under which Seattle Genetics has U.S. and Canadian commercialization rights and Millennium has exclusive rights to commercialize the product in the rest of the world. Seattle Genetics and Millennium are jointly funding worldwide development costs for brentuximab vedotin on a 50:50 basis. Additionally, Seattle Genetics has nine ongoing ADC collaborations with leading biotechnology and pharmaceutical companies. To date, Seattle Genetics has generated approximately $110 million through ADC technology license agreements.

SOURCE Seattle Genetics, Inc.